65,437 trials
Gastric Cancer
Primary: Progression-Free Survival (PFS) in All Randomized Participants and Participants With PTEN Loss Tumors at Primary Analysis — 6.57; 7.52; 7.10; 7.39 months — p== 0.56
Atherosclerotic Cardiovascular Disease
Primary: Platelet Reactivity Defined by VerifyNow PRU in HPR and NPR Patients — 219; 241; 141; 159 PRU — p=0.169
Non-Hodgkin's Lymphoma · Hodgkin Lymphoma · Multiple Myeloma
Primary: Number of Participants That Experienced Drug Related Grade 3-4 AEs — 19; 18; 0 Participants
COVID19
Primary: Number of Subjects for Which the Prototype Swab and the Control Swab Provide the Same COVID-19 PCR Result — 18; 17; 22; 23 participants
Benign Prostatic Hyperplasia (BPH)
Primary: International Prostate Symptom Score (IPSS) Change From Baseline to the Last Follow-up Date, Anywhere Between Month 3 - Month 6 Post Rezūm Procedure. — 14.9 scores on a…
Prostate Cancer
Primary: Overall Survival (Favorable and Unfavorable ) — 13.9; 36.3 months
Epilepsy, Idiopathic Generalized
Primary: Time to First Seizure — 169; 178 Days
Bipolar Disorder · Medication Adherence · Medication Non Adherence
Primary: Change in Tablets Routine Questionnaire (TRQ, Past Week) — 50.1; 37.5; 16.9 percentage of missed BD medications — p=<0.001
Phenylketonuria (PKU)
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) as Assessed by CTCAE v5.0 — 36; 17; 7; 1 Participants
Sarcopenia
Primary: Changes in Hand Grip Strength — 29.2; 29.5; 35.3; 30.3 kg — p=<0.05
Anatomic Stage II Breast Cancer AJCC v8 · Anatomic Stage IIA Breast Cancer AJCC v8 · Anatomic Stage IIB Breast Cancer AJCC v8
Primary: Feasibility of Enrolling 15 Patients Within 2 Years — 8 Participants
Crohn Disease
Primary: Part I: Change From Baseline in the Crohn's Disease Activity Index (CDAI) Score at Week 8 — -60.0; -103.6 units on a scale
Healthy
Primary: Mean 40-Hz Auditory Steady State Response Power — 0.34; 0.43; 0.60 uV^2
Spinal Cord Injury
Primary: Time Required to Walk 10 Meters in Seconds as Measured by the Ten Meter Walk Test (10MWT) — 38.3; 28.0; 37.2; 27.9 Seconds
Human Immunodeficiency Virus · Smoking
Primary: Number of Participants Who Participate in the Post-treatment Interview — 9 Participants